The relationship between expression of p53/bcl-2 and clinicopathological criteria in endometrioid adenocarcinomas of the endometrium

Objective: Thirty patients with endometrioid adenocarcinomas of the endometrium who had undergone total abdominal hysterectomy and bilateral salpingo-oophorectomy were reviewed histopathologically.

Materials and methods: Tissues were stained immunohistochemically with p53 and bcl-2, respectively. Ten cases were selected as grade 1, ten cases grade 2 and ten cases grade 3.

Results: We observed 14 cases (46.6%) of bcl-2 and four cases (13.3%) of p53 positivity; p53 expression showed an opposite correlation to bcl-2 staining, estrogen and progesterone.

Conclusion: We observed a decrease in bcl-2 reactivity and an increase in p53 positive staining as the histological differentiation worsened.

p53; bcl-2; Endometrioid adenocarcinomas; Endometrium

[1] Kromer G.:'The protooncogene bcl-2 and its role in regulating apoptosis". Nat. Med., 1997, 3, 614.

[2] Mc Donnel T.J. et al.: "Importance of the bcl-2 family in cell death regulation". Experientia, 1996, 52, 1008.

[3] Vogelstein B., Kinzler K.W.: "p53 function and dysfunction". Cell, 1993, 70, 523.

[4] Gompel A., Sabourin J.C., Mortin A., Yaneva H., Avdoin J., Decroix Y. et al.: "Bcl-2 expression in normal endometrium during the menstrual cycle". Am. J. Pathol., 1994, 144, 1195.

[5] Geisler J.P., Geisler H.E., Wiemann M.C., Zhou Z., Miller G.A., Craptree W.: "Lack of bcl-2 persistance: an independent prognostic indicator of poor prognosis in endometrial carcinoma". Gynecol. Oneal., 1998, 71, 305.

[6] Morris P.C., Anderson J.R., Anderson B., Buller R.E.: "Steroid hormone receptor content and lymph node status in endometrial cancer". Gynecol. Oneal., 1995, 56, 406.

[7] Sacgusa M., Okayasu I.: "Bcl-2 is closely correlated with favorable prognostic factors and inversely associated with p53 protein accumulation in endometrial carcinomas". J. Cancer Res. Clin. Oneal., 1997, 123, 429.

[8] Taskin M., Lallas T.A., Barker H.R., Shevchuk M.M.: "Bcl-2 and p53 in endometrial adenocarcinomas". Mod. Pathol., 1997, 10, 728.

[9] Sakuragi N., Ohkovchi T., Hareyama H., Ikeda K., Walori H., Fujimoto T. et al.: "Bcl-2 expression and prognosis of patients with endometrial carcinoma". Int. J. Cancer, 1998, 79, 153.

[10] Geisler J.P., Wiemann M.C., Zhoo Z., Miller G.A., Geisler he "p53 as a prognostic indicator in endometrial cancer". Gynecol Oneal., 1996, 61, 245.

[11] Yamovchi N., Sakamoto A., Vozaki H., Tihara K., Machinami R. "Immunohistochemical analysis of endometrial adenocarcinoma for bcl-2 and p53 in relation to expression of sex steroid receptor and proliferative activity". Int. J. Gynecol. Pathol., 1996, 15, 202.

[12] Hamel N.W., Sebo T.J., Wilson T.O., Keeney G.L., Roche P.C., Suman VJ. et al.: "Prognostic value of p53 and proliferating cell nuclear antigen expression in endometrial carcinoma". Gynecol. Oneal., 1996, 62, 192.

[13] Lax S.F., Pizer E.S., Ronnet B.M., Koran R.J.: "Comprasion of estrogen and progesterone receptor, K67, and p53 immunoreactivity in uterine endometrioid carcinoma, endometrioid carcinoma with squamous, mucinous, secretary, and ciliated cell differentiation". Human. Pathol., 1998, 29, 924.

[1l4] Niessen A.L., Nyholm H.C.: "p53 protein and c-erb B-2 protem (pl85) expression in endometrial adenocarcinoma of endometrioid type. An immunohistochemical examination of paraffin sections". Am. J. of Pathol., 1994, 102, 76.

[15] Parozzini F., La Veschia C., Negri E., Maroni S., Chatenoud L "Smoking and risk of endometrial cancer: results from an Italian case-control study". Gynecol. Oncol., 1995, 56, 195.